Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Upneeq in acquired blepharoptosis
NCT03536949Phase 3Completed
- Sponsor
- RVL Pharmaceuticals
- Start
- Jun 2018
- Primary completion
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in acquired blepharoptosis comparing RVL-1201 with Vehicle (2 arms). Primary endpoints: Intraocular Pressure at Day 84 and Pupil Diameter at Day 84. Started Jun 2018; status: completed.
02
Drugs
oxymetazoline
03
Conditions
acquired blepharoptosis
Beyond the preview
Go deeper on NCT03536949.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03536949.